Skip to main content

Table 1 Initial clinical data at the baseline

From: Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study

General information

Sacubitril/valsartan (n = 106)

Valsartan (n = 106)

P

Age (years)a

69.50 ± 11.88

69.04 ± 13.09

0.788

Gender [n(%)]

  

0.773

    Male

68(64.2%)

70(66.0%)

 

    Female

38(35.8%)

36(34.0%)

 

SBP (mmHg) a

146.35 ± 20.19

148.27 ± 26.53

0.553

DBP (mmHg) a

82.01 ± 13.18

82.57 ± 13.78

0.764

BMI (kg/m2) a

25.01 ± 3.63

25.01 ± 3.33

0.997

Past history [n(%)]

   

    Hypertension

67(63.2)

78(73.6)

0.104

    Diabetes

50(47.2)

47(44.3)

0.679

    Coronary artery disease

69(65.1)

60(56.6)

0.205

    Hyperlipidemia

53(50.0)

55(51.9)

0.783

Medication history [n(%)]

   

    Beta-blockers

78(73.6)

71(67.0)

0.293

    Calcium channel blocker

39(36.8)

45(42.5)

0.400

    Diuretics

71(67.0)

65(61.3)

0.390

    Aldosterone antagonists

54(50.9)

56(52.8)

0.783

    SGLT2-i

27(25.5)

23(21.7)

0.518

    Insulin

31(29.2)

30(28.3)

0.879

    Hormone

6(5.7)

2(1.9)

0.280

    Ezetimibe

6(5.7)

5(4.7)

0.757

   Statins

79(74.5)

87(82.1)

0.183

NYHA class [n(%)]

  

0.372

    Class II

27(25.5)

21(19.8)

 

    Class III

59(55.7)

69(65.1)

 

    Class IV

20(18.9)

16(15.1)

 

TG (mmol/L)b

1.87(1.65,2.32)

1.84(1.35,2.36)

0.254

TC (mmol/L) a

4.46 ± 1.28

4.51 ± 1.35

0.780

HDL-C (mmol/L) a

1.10 ± 0.31

1.13 ± 0.33

0.528

LDL-C (mmol/L) a

2.60 ± 1.04

2.68 ± 1.15

0.589

ApoA (mmol/L) a

1.12 ± 0.25

1.13 ± 0.24

0.809

ApoB (mmol/L) a

0.87 ± 0.28

0.89 ± 0.3

0.648

Albumin(g/L) a

39.57 ± 7.04

40.4 ± 5.69

0.349

Creatinine (umol/L)b

115.00(101.00,153.00)

123.00(106.00,159.00)

0.186

eGFR (mL/min)b

49.62(34.76,58.65)

46.45(36.09,55.14)

0.294

Cystatin C (mg/L) b

1.56(1.34,1.96)

1.45(1.22,1.96)

0.254

Uric acid (umol/L)b

441.50(357.00,542.25)

444.00(338.00,530.50)

0.712

Urea (mmol/L) b

9.75(7.60,13.93)

9.49(7.20,13.60)

0.633

FBG (mmol/L) a

6.85 ± 2.76

6.60 ± 2.70

0.517

HbA1c(%)a

7.01 ± 1.77

6.96 ± 1.53

0.835

Potassium (mmol/L) a

4.18 ± 0.42

4.20 ± 0.38

0.674

High-sensitive troponin T (ng/L) b

32.05(21.51,50.28)

31.47(23.25,42.15)

0.923

NT-proBNP (pg/mL) b

3607.10(1912.00,6388.30)

3006.50(1179.59,7190.28)

0.306

LVEF(%)a

45.11 ± 10.62

46.63 ± 11.14

0.311

LVEDD (mm) a

59.76 ± 9.32

58.57 ± 9.28

0.349

LAD (mm) a

46.02 ± 7.17

44.73 ± 7.21

0.192

  1. Abbreviations used in the table include SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, SGLT2-i sodium-glucose cotransporter 2 inhibitors, NYHA New York Heart Association, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ApoA apolipoprotein A, ApoB apolipoprotein B, eGFR estimated glomerular filtration rate, FBG fasting blood glucose, HbA1c hemoglobin A1c, NT-proBNP N-terminal pro-brain natriuretic peptide, LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic diameter, LAD left atrial diameter, and n number of patients
  2. aMedian (standard deviation)
  3. bMedian (interquartile range)
  4. The normality of the measurement data is assessed using the Shapiro-Wilk test. No notable distinctions are observed in the baseline characteristics between groups